Featured Publications
Titration of RAS alters senescent state and influences tumour initiation
Chan A, Zhu H, Narita M, Cassidy L, Young A, Bermejo-Rodriguez C, Janowska A, Chen H, Gough S, Oshimori N, Zender L, Aitken S, Hoare M, Narita M. Titration of RAS alters senescent state and influences tumour initiation. Nature 2024, 633: 678-685. PMID: 39112713, PMCID: PMC11410659, DOI: 10.1038/s41586-024-07797-z.Peer-Reviewed Original ResearchConceptsTumor typesOncogenic RAS-induced senescenceInfluence tumor initiationProgenitor-like featuresTumor-initiating phenotypeSingle-cell RNA sequencing analysisModel in vivoHCC subclassesModel in vitroHepatocellular carcinomaTumor suppressor mechanismEarly tumorigenesisTumor initiationEarly-onsetProgenitor featuresInduce tumorsSuppressor mechanismTumorLate-onsetRNA sequencing analysisOncogenic stressRas-induced senescenceIn vivoMolecular signaturesOncogene dosage
2023
Cancer Evolution: A Multifaceted Affair
Ciriello G, Magnani L, Aitken S, Akkari L, Behjati S, Hanahan D, Landau D, Lopez-Bigas N, Lupiáñez D, Marine J, Martin-Villalba A, Natoli G, Obenauf A, Oricchio E, Scaffidi P, Sottoriva A, Swarbrick A, Tonon G, Vanharanta S, Zuber J. Cancer Evolution: A Multifaceted Affair. Cancer Discovery 2023, 14: of1-of13. PMID: 38047596, PMCID: PMC10784746, DOI: 10.1158/2159-8290.cd-23-0530.Peer-Reviewed Original ResearchConceptsEvolutionary mechanismsMultiple evolutionary mechanismsCancer evolutionHeritable genetic changesTumor evolutionImprove personalized medicineEpigenetic reprogrammingGenetic changesTumor microenvironmentGenetic instabilityCancer hallmarksEvolutionary toolkitNongenetic mechanismsCancer cellsPersonalized medicineBiomarker discoveryTumor cellsTumor progressionTumorComprehensive characterizationMolecular modificationsCancerCellsChromatinReprogramming
2009
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases
Aitken S, Thomas J, Langdon S, Harrison D, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Annals Of Oncology 2009, 21: 1254-1261. PMID: 19858088, DOI: 10.1093/annonc/mdp427.Peer-Reviewed Original ResearchConceptsNodal diseaseReceptor statusPrimary tumorAdjuvant therapyHER2 expressionReceptor expressionInvasive primary breast carcinomasPaired lymph nodeQuantitative receptor expressionPrimary breast carcinomaPrimary breast cancerResistance to therapyExpression of molecular markersNodal metastasisBreast carcinomaLymph nodesTherapeutic resistanceBreast cancerQuantitative immunofluorescenceClinical trialsTumorImmunohistochemistryTherapyPatientsMolecular phenotypes